New players in ovarian cancer

Journal of Cellular Physiology

Volumn 226, Issue 10, 2011, Pages 2500-2504

  Bovicelli, Alessandro ^a,b   D'Andrilli, Giuseppina ^a   Giordano, Antonio ^a,c  

^a Temple University   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; CYCLIN D; CYCLOSPORIN A; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; MICRORNA; PACLITAXEL; TRANSCRIPTION FACTOR; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL CYCLE REGULATION; DOWN REGULATION; HUMAN; NONHUMAN; OVARY CARCINOMA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE; VIRAL GENE THERAPY;

ANTINEOPLASTIC AGENTS; CELL CYCLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICRORNAS; OVARIAN NEOPLASMS; TRANSCRIPTION FACTORS;

EID: 79960682406     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22662     Document Type: Review

References (37)

1. Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC, Jr., Kruk PA. 2009. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol 112: 60-67.
2. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA. 2006. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43.
3. Bartels CL, Tsongalis GJ. 2009. MicroRNAs: Novel biomarkers for human cancer. Clin Chem 55: 623-631.
4. Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow RE, Mazitschek R, Bradner J, Roden RB. 2008. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 14: 7340-7347.
5. Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL II, Meisner BC, Armstrong DK, Frick KD. 2007. Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: A cost-effectiveness analysis. Gynecol Oncol 106: 476-481.
6. Cancer Facts & Figures. 2009. Atlanta: American Cancer Society 2009; 1-68.
7. Chao KC, Chang CC, Yen MS, Wang PH. 2010. Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells. Eur J Gynaecol Oncol 31: 402-410.
8. Chaudhry P, Srinivasan R, Patel FD. 2010. Expression of the major fas family and Bcl-2 family of proteins in epithelial ovarian cancer (EOC) and their correlation to chemotherapeutic response and outcome. Oncol Res 18: 549-559.
9. Creighton CJ, Fountain MD, Yu Z, Nagaraja AK, Zhu H, Khan M, Olokpa E, Zariff A, Gunaratne PH, Matzuk MM, et al. 2010. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res 70: 1906-1915.
10. D'Andrilli G, Masciullo V, Bagella L, Tonini T, Minimo C, Zannoni GF, Giuntoli RL II, Carlson JA, Jr., Soprano DR, Soprano KJ, et al. 2004. Frequent loss of pRb2/p130 in human ovarian carcinoma. Clin Cancer Res 10: 3098-3103.
11. De Meyer T, Bijsmans IT, Van de Vijver KK, Bekaert S, Oosting J, Van Criekinge W, van Engeland M, Sieben NL. 2009. E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas. J Pathol 217: 14-20.
12. Duncan TJ, Al-Attar A, Rolland P, Harper S, Spendlove I, Durrant LG. 2010. Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer. Int J Gynecol Pathol 29: 8-18.
13. Feng G, Li G, Gentil-Perret A, Tostain J, Genin C. 2008. Elevated serum-circulating RNA in patients with conventional renal cell cancer. Anticancer Res 28: 321-326.
14. Goto T, Takano M, Hirata J, Kohno T, Ohtsuka S, Fujiwara K, Tsuda H. 2009. p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer. Int J Cancer 125: 339-344.
15. Hayashi A, Horiuchi A, Kikuchi N, Hayashi T, Fuseya C, Suzuki A, Konishi I, Shiozawa T. 2010. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin. Int J Cancer 127: 1332-1346.
16. Imam JS, Buddavarapu K, Lee-Chang JS, Ganapathy S, Camosy C, Chen Y, Rao MK. 2010. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene 29: 4971-4979.
17. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC, Lee HP. 2009. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res 18: 47-56.
18. Kothandaraman N, Bajic VB, Brendan PN, Huak CY, Keow PB, Razvi K, Salto-Tellez M, Choolani M. 2010. E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer 10: 64.
19. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, et al. 2008. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 141: 672-675.
20. Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM, Yao TP. 2008. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res 68: 7561-7569.
21. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. 2009. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 4: e6229.
22. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. 2007. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res 67: 1017-1022.
23. Masamha CP, Benbrook DM. 2009. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res 69: 6565-6572.
24. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Jr., Skates SJ. 2009. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 112: 40-46.
25. Moore RG, MacLaughlan S, Bast RC, Jr. 2010. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol 116: 240-245.
26. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Muller-Holzner E, Marth C, Zeimet AG. 2007. Clinical relevance of E2F family members in ovarian cancer-an evaluation in a training set of 77 patients. Clin Cancer Res 13: 144-151.
27. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. 2008. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111: 478-486.
28. Takai N, Narahara H. 2007. Human endometrial and ovarian cancer cells: Histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr Med Chem 14: 2548-2553.
29. Takai N, Narahara H. 2010. Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J Oncol 2010: 458431.
30. Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F, Adair B, Vannini I, Fanini F, Bottoni A, et al. 2010. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 107: 6982-6987.
31. Wang Y, Wang Y, Cheng C, Ji Y, Zhao Y, Zou L, Shen A. 2009. Expression of Jun activation domain-binding protein 1 and Ser10 phosphorylated p27 protein in human epithelial ovarian carcinoma. J Cancer Res Clin Oncol 135: 951-959.
32. Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, Schiff PB, Herzog TJ. 2009. Fertility preservation in young women with epithelial ovarian cancer. Cancer 115: 4118-4126.
33. Yamaguchi H, Chen CT, Chou CK, Pal A, Bornmann W, Hortobagyi GN, Hung GN. 2010. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation. Oncogene 29: 5619-5629.
34. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, et al. 2008a. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433.
35. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, Liang S, Leminen A, Deng S, Smith L, et al. 2008b. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68: 10307-10314.
36. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, et al. 2008. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 105: 7004-7009.
37. Zhou Q, Melkoumian ZK, Lucktong A, Moniwa M, Davie JR, Strobl JS. 2000. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J Biol Chem 275: 35256-35263.